Articles On Respiri (ASX:RSH)

Respiratory health focused Respiri (ASX: RSH) has bedded-in support for its wheezo device and platform after Pharmacy Platform member Pharmacy Catalyst confirmed it will begin the wheezo in-pharmacy asthma patient program next month. Pharma...

Zip Co Ltd (ASX: Z1P) shares struggled in the second half of 2020 despite the company’s strong growth performance and positive announcements. With everything that’s going for the buy now, pay later (BNPL) company, why has the Zip share pri...

Special Report: Respiratory health company Respiri has entered into a sales and marketing partnership for its wheezo devices for asthma ... Read More The post Respiri rolls out wheezo device distribution with Pharmacy 4 Less group appeared...

Respiratory health technology company Respiri (ASX: RSH) has announced a new sales and marketing partnership with the Pharmacy 4 Less group for the sale of its asthma management device wheezo commencing early next year. This is the second p...

Immutep Limited (ASX: IMM) announced that its Chinese partner, EOC Pharma, will begin a new Phase II clinical trial on up to 152 metastatic breast cancer patients in China. Immutep Limited is a biotechnology company, which develops novel i...

Special Report: Respiri’s deal with Cipla will allow it to boost distribution of its wheezo asthma management device via direct ... Read More The post Respiri reasserts full-year revenue guidance after locking in key product order, shares c...

Demand for Respiri’s (ASX: RSH) wheezo asthma management device has continued to grow following the platform’s recent commercial launch in Australia with sales orders increasing and a new banner partnership announced. The respiratory health...

Summary Despite the challenges imposed by COVID-19, Volpara Heath delivered a substantial 38% revenue growth. Metrics such as gross margin and group ARPU also improved over the previous corresponding period. In 2H FY2021, Volpara would...

Three months after announcing the start of a co-major partnership with Carlton Football Club, health technology developer Respiri (ASX: RSH) has revealed its product logo will adorn the club’s official women’s uniform and training gear next...

It’s been a bumpy road of development for Respiri Ltd [ASX:RSH]. Today though, with an early gain of 12.9%, The RSH share price seems to be heading back in the right direction. So, what was behind the turnaround? The post Respiri Reports Re...

With Respiri’s (ASX: RSH) stage launch of wheezo across select Australian pharmacies and online underway, the company has revealed further major cost reductions resulting in improved margins. The cost reductions are a result of “significant...

Special Report: Respiri Limited’s (ASX:RSH) expects its gross product margins for its wheezos to be 30 per cent higher than ... Read More The post Respiri details ‘exceptional’ cost savings to wheezo production appeared first on Stockhead.

Respiratory health management company Respiri (ASX: RSH) has updated the market regarding the preliminary release of its wheezo platform and device, saying it was “very pleased” with the responses it has received from pharmacists and partne...

Summary ASX-listed eHealth SaaS Company Respiri Limited filed for an additional patent application for asthma management device- wheezo. The additional patent filing was based on advancements made to the wheezo™ algorithm during the pre...

Respiratory-focused eHealth company Respiri (ASX: RSH) has filed an additional patent application based on recent improvements made to the algorithm for its wheezo asthma management device. The new intellectual property relates principally...

Special Report: Melbourne-based asthma assessment company Respiri is taking steps to protect its commercial advantage before its Australian launch with ... Read More The post Respiri takes steps to secure intellectual property with another...

Openpay Group Ltd (ASX: OPY) has achieved record growth in the first quarter of FY21, potentially opening the way for the Openpay share price to reverse the losses over the past month. This includes increases in active customers by 145% an...

Special Report: Respiri Limited has completed an oversubscribed $12.5 million to fund the launch of its wheezo asthma management device. ... Read More The post Investors line up to give Respiri cash as wheezo launches into Australian pharma...

Summary Respiri Limited announced the successful completion of a $12.5 million share placement. The Company would issue 62.5 million shares at $0.20 per share at a healthy discount of 6.5% to the VWAP of the last 30 days. Proceeds from...

eHealth company Respiri (ASX: RSH) has completed a $12.5 million capital raising targeted at the commercial launch of its proprietary wheezo asthma management platform in Australia before year end. The raising was conducted via the issue of...

SaaS health company Respiri was cap in hand in front of investors on Wednesday morning, as it gears up to launch its flagship asthma management product.

At time of writing, the Respiri Ltd [ASX:RSH] share price is up 4.55%, trading at 23 cents. The Melbourne-based biotech company recently announced a manufacturing partner for their new product, wheezo™... The post Respiri Share Price Jumps...

The Respiri Limited (ASX: RSH) share price is up 6.82% to 23.5 cents in early afternoon trading. The surge in the Respiri share price comes following the company’s announcement this morning of a binding electronic manufacturing services (E...

Health technology company Respiri (ASX: RSH) has engaged Entech Electronics to manufacture its “ground breaking” wheezo device offshore in China, which is expected to “significantly improve” production costs. South Australia-based electroni...

ASX telehealth stocks have had a solid six months, gaining 25 per cent, but there are warnings more has to be done to maintain the run. The breakout of COVID-19 resulted in wide-spread adoption of telehealth as medical professionals were fo...

The share price of medical technology company Respiri Ltd [ASX:RSH] has pushed higher today thanks to positive results from its latest clinical study. At the time of writing, RSH shares had pushed 3.23% higher to trade at 1.6 cents... The p...

Preliminary results of a clinical study involving the wheezo asthma management platform made by eHealth technology developer Respiri (ASX: RSH) has shown the device is capable of accurately detecting the presence or absence of wheeze in pat...

Special Report: Respiri remains on track to commercialise its wheezo asthma detection device before the end of the year. eHealth company Respiri (ASX:RSH) has continued its run of positive news flow, with the release of new clinical trial d...

Special Report: Respiri ‘kicks a ton’ with new Carlton Football Club AFLW team partnership. Ehealth business Respiri (ASX:RSH) has taken its biggest mark yet for 2021, signing on with the Carlton Football Club’s AFLW team for the upcoming...

A day after publishing its full year accounts, eHealth company Respiri (ASX: RSH) has tentatively set foot in Australian rules football courtesy of a partnership with Carlton Football Club AFLW, commencing from next season. More specificall...

It’s been a mixed year for Respiri Ltd [ASX:RSH]. With markets gripped by the COVID-19 pandemic, shares in the company took a hit. But that didn’t stop the ongoing development of their respiratory monitoring device: wheezo... The post Respi...

eHealth company Respiri (ASX: RSH) has taken another step towards growing sales of its wheezo device ahead of its October launch, after signing a three-year product referral agreement (PRA) with the Australian Patients Association (APA). Th...

StockTalk is a Stockhead video series featuring a roundtable of experts discussing a new investment topic each week. In this edition, host Dr Nigel Finch discusses skyrocketing healthcare spending and its impact on the medtech sub-sector. P...

eHealth Software-as-a-Service (Saas) company Respiri (ASX: RSH) has updated the market with news it has entered into a partnership with the Australian Patients Association (APA) to support asthma sufferers through its wheezo experiential pr...

Telehealth use has only continued to increase as COVID-19 wore on throughout May and June. Both listed and non-listed plays such as healthcare booking service HealthEngine saw demand rise exponentially as the pandemic broke out and this has...

eHealth technology developer and maker of the wheezo device, Respiri (ASX: RSH) has published interim revenue guidance for 2021 with total revenues from both device and software subscription estimated to reach $6-$8 million. Wheezo is a mod...

Special Report: Respiratory health company Respiri has signed on to Zip Money, a move it expects to boost revenue by 10 per cent. Respiratory health company Respiri (ASX:RSH) has signed on with Zip Co (ASX:Z1P) and says the deal should add...

Respiri (RSH) has signed a merchant services agreement with buy now, pay later giant Zip Co's (Z1P) subsidiary, Zip Money Payments; As more ...

Wheezo developer Respiri’s (ASX: RSH) commercialisation path will accelerate even further after the company collared a deal with renowned buy now pay later provider Zip Co Ltd (ASX: Z1P). Respiri chief executive officer Marjan Mikel said th...

The Respiri Ltd (ASX: RSH) share price has today reached 52-weeks highs, following news that the eHealth company signed a merchant services agreement with major payments share Zip Co Ltd (ASX: Z1P). The Respiri share price is currently tra...

For those with existing respiratory illnesses, like asthma, it has been an even more challenging time. COVID-19 being a far more deadly threat. Which is precisely why companies like Respiri Ltd [ASX:RSH] and their technology are so importan...

A quick wrap of the ASX’s key winners and losers on Friday, July 17. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made market-moving announcements during the day. Today 712 stocks rose, 606 declined and 789...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Special Report: Respiri’s biggest ever sales agreement will yield significant sales in the first 12 months. Respiri (ASX:RSH), a company whose respiratory monitoring device has been making waves since the COVID-19 pandemic began, has signed...

Healthcare technology developer Respiri (ASX: RSH) has signed an exclusive agreement with global respiratory pharmaceutical firm Cipla for the sales and distribution of Respiri’s wheezo asthma product to its target markets. The five-year ag...

Medical technology is a broad field covering areas like biotechnology, pharmaceuticals, and information technology. Advancements in medical technology improve the way doctors diagnose and treat patients, leading to better health outcomes....

Special Report: The agreement will see data from Respiri’s propriety wheezo technology collated to improve outcomes for asthma research. For electronic health company Respiri (ASX:RSH), the focus is now on expanding the global distribution...

eHealth software company Respiri (ASX: RSH) has unveiled a new partnership agreement with the University of Edinburgh to feed data from its proprietary Wheezo devices into a new data research centre in the UK to advance research into respir...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Clinical t...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Clinical t...